Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials
Gennaro Pagano, Dylan Trundell, Tanya Simuni, Nicola Pavese et autres
0 citationsnpj Parkinson s Disease
Paulo Fontoura
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
153Publications signalées
14102Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
Alzheimer's disease research and treatmentsMultiple Sclerosis Research StudiesNeurogenetic and Muscular Disorders ResearchParkinson's Disease Mechanisms and TreatmentsHealth Systems, Economic Evaluations, Quality of Life
Publications récentes
Risdiplam in Presymptomatic Spinal Muscular Atrophy
Richard S. Finkel, D. Vlodavets, Edmar Zanoteli, Maria Mazurkiewicz-Bełdzińska et autres
36 citationsNew England Journal of Medicine
The UBE3A-ATS antisense oligonucleotide rugonersen in children with Angelman syndrome: a phase 1 trial
Joerg F. Hipp, Carlos A. Bacino, Lynne M. Bird, Ina Bruenig-Traebert et autres
29 citationsNature Medicine
Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab
Kirsten I. Taylor, Florian Lipsmeier, Marzia A. Scelsi, Ekaterina Volkova-Volkmar et autres
14 citationsnpj Digital Medicine
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial
Randall J. Bateman, Yan Li, Eric McDade, Jorge J. Llibre‐Guerra et autres
52 citationsThe Lancet Neurology
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data
Tania Nikolcheva, Gennaro Pagano, Nathalie Pross, Tanya Simuni et autres
16 citationsParkinsonism & Related Disorders
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD)
Merçé Boada, Anuja Neve, Bibha Das, Jakub Wojtowicz et autres
2 citationsJournal of Alzheimer s Disease
Randomized trial of BCG in healthcare workers to reduce absenteeism during the COVID-19 pandemic in sub-Saharan Africa
I Silva, Lídia Nhamússua, Elsi Cá, Frederik Schaltz‐Buchholzer et autres
4 citationsTransactions of the Royal Society of Tropical Medicine and Hygiene
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial
Randall J. Bateman, Yan Li, Eric McDade, Jorge J. Llibre‐Guerra et autres
6 citationsmedRxiv
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial
Jerry R. Mendell, Francesco Muntoni, Craig M. McDonald, Eugenio Mercuri et autres
170 citationsNature Medicine
Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial
Gennaro Pagano, Annabelle Monnet, Benjamin Ribba, Hanno Svoboda et autres
58 citationsNature Medicine
21O RAINBOWFISH: 2-year efficacy and safety data of risdiplam in infants with presymptomatic SMA
Laurent Servais, R. Finkel, Michelle A. Farrar, D. Vlodavets et autres
3 citationsNeuromuscular Disorders
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.